{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-029227","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2024-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.585187+00:00","generated_at":"2026-05-31T15:55:57.438273+00:00","sec_items":["5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"MyMD Pharma rebrands to TNF Pharmaceuticals; ticker changes to TNFA on Nasdaq","bullets":["Name changed from MyMD Pharmaceuticals to TNF Pharmaceuticals effective July 22, 2024.","Common stock began trading under new ticker 'TNFA' on Nasdaq effective July 24, 2024, replacing 'MYMD'.","Rebranding aligns with therapeutic focus on TNF-alpha inhibition; lead candidate MYMD-1 unchanged.","No change to CUSIP or shareholder action required; stockholder approval was not needed.","Company plans mid-stage clinical trials of MYMD-1 for sarcopenia following positive Phase 2 results."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-029227","json":"https://secwatch.observer/filing/0001493152-24-029227.json","markdown":"https://secwatch.observer/filing/0001493152-24-029227.md","text":"https://secwatch.observer/filing/0001493152-24-029227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315224029227/0001493152-24-029227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315224029227/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:55:57.438273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}